- Collaborations with Keck School of Medicine of USC, University of Alabama School of Medicine, and Westchester Medical Center at New York Medical College provide insight into the diagnosis and management of challenging cancers.
- The collaborations leverage the power of CGI's unique, proprietary genomic panels, including MatBA® for diffuse large B-cell lymphoma (DLBCL), which is the only clinically available panel that can stratify lymphoma patients and predict those most likely to relapse.
RUTHERFORD, N.J., March 23, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company") announced today that it will present three posters at USCAP, the annual meeting of the United States and Canadian Academy of Pathology, March 23-24 at the Hynes Convention Center in Boston, MA. The presentations will feature the results of several clinical research collaborations aimed at providing better insight into the molecular basis of poorly understood cancers in order to drive improved diagnosis and patient management. Each of the collaborations leveraged CGI's proprietary genomic panels for their investigation.
Cancer Genetics' collaboration with the Keck School of Medicine of University of Southern California (USC), examines the relationship of genetic markers and pathologic features to clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients. Results will be presented on Monday, March 23 at 1:00 pm ET in a poster entitled "MYC/TP53 Coexpression and Loss of 17p13 are Independently Associated with Inferior Survival in Diffuse Large B-Cell Lymphoma (DLBCL)" by Charles Ma, Ph.D., principal research scientist at Cancer Genetics, Inc. DLBCL is the most common form of non-Hodgkin lymphoma (NHL), representing 25-30% of all NHL cases. As the population continues to age, incidence of DLBCL is expected to rise, creating increasing demand for genetic tests such as CGI's MatBA®-DLBCL. CGI's genomic panel for DLBCL is better able to differentiate between patients that are likely to be cured from those that are likely to relapse.
Results of a collaboration with the University of Alabama (UAB) School of Medicine on primary central nervous system lymphomas (PCNSL) will be presented in a poster, "Molecular Cytogenetic Features of Primary Central Nervous System Lymphoma" by Deniz Peker, MD, of the UAB School of Medicine. Primary central nervous system lymphomas (PCNSL) are a group of poorly understood aggressive cancers. This study used CGI's array-CGH (comparative genomic hybridization) techniques to identify chromosomal changes in PCNSL to better understand the biomarkers associated with these diseases. The poster will be presented on Monday, March 23 at 1:00 pm ET.
A third poster, "Immunohistochemistry Stain and Molecular Genetic Study on Hemangioblastoma: An Indication of Anti-VEGF Target Therapy," will report results of a study conducted in collaboration with Westchester Medical Center at New York Medical College. Hemangioblastomas are slow-growing tumors of the central nervous system for which no targeted therapies are currently available. Anti-VEGF target therapy was investigated as a possible treatment for hemangioblastomas due to its morphological similarity to clear cell renal cell carcinoma. CGI's proprietary array-CGH panel UroGenRA®-Kidney was critical in assessing the comparative genomic gains and losses involved. The poster will be presented by Sabina Babayeva from Westchester Medical Center on Tuesday, March 24 at 9:30 am ET.
According to Panna Sharma, CEO of Cancer Genetics, Inc., "The research results being presented at USCAP this week demonstrate our continued focus on the validation of our unique technology to improve patient management. Our tests are helping researchers to develop novel and targeted insights into the molecular basis of poorly understood cancers to drive improvements in diagnosis and patient management."
The USCAP meeting will take place at the Hynes Convention Center in Boston, March 21-27. Representatives from the company will be exhibiting in booth 716 at the 2015 USCAP Annual Meeting Expo from March 22-26.
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future developments in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.